Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $30.00.

KYTX has been the topic of a number of analyst reports. Wall Street Zen downgraded shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. JPMorgan Chase & Co. cut their price objective on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 13th. HC Wainwright lifted their price objective on shares of Kyverna Therapeutics from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, May 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Friday, March 27th.

Kyverna Therapeutics Trading Down 1.5%

NASDAQ KYTX opened at $8.52 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 8.15 and a current ratio of 8.15. The company has a market capitalization of $517.93 million, a price-to-earnings ratio of -2.60 and a beta of 2.05. The company’s 50-day simple moving average is $9.03 and its two-hundred day simple moving average is $8.50. Kyverna Therapeutics has a one year low of $2.47 and a one year high of $13.67.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its earnings results on Tuesday, May 12th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.09. Equities analysts forecast that Kyverna Therapeutics will post -2.81 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio purchased a new stake in Kyverna Therapeutics during the 3rd quarter worth approximately $28,000. Qube Research & Technologies Ltd purchased a new stake in Kyverna Therapeutics during the 2nd quarter worth approximately $43,000. Rhumbline Advisers grew its stake in Kyverna Therapeutics by 22.0% during the 1st quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock valued at $61,000 after purchasing an additional 5,694 shares during the last quarter. Ameriprise Financial Inc. purchased a new stake in Kyverna Therapeutics during the 3rd quarter valued at about $77,000. Finally, Bank of America Corp DE grew its stake in Kyverna Therapeutics by 41.6% during the 4th quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock valued at $81,000 after purchasing an additional 6,400 shares during the last quarter. 18.08% of the stock is currently owned by hedge funds and other institutional investors.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.